A Study Investigating the Efficacy and Safety of Intravitreal Injections of ANX007 in Patients With Geographic Atrophy

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2021
This study is being conducted in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) to determine if intravitreal (IVT) injections of ANX007 reduce GA lesion growth rate. The results will be used to guide further development of ANX007 in participants with geographic atrophy. The total duration of participation is expected to be approximately 19 months.
Epistemonikos ID: b082e5bad30def1d298dee90846b3fc8bb5aebe4
First added on: May 07, 2024